CA2612240A1 - Genes of an otitis media isolate of nontypeable haemophilus influenzae - Google Patents

Genes of an otitis media isolate of nontypeable haemophilus influenzae Download PDF

Info

Publication number
CA2612240A1
CA2612240A1 CA002612240A CA2612240A CA2612240A1 CA 2612240 A1 CA2612240 A1 CA 2612240A1 CA 002612240 A CA002612240 A CA 002612240A CA 2612240 A CA2612240 A CA 2612240A CA 2612240 A1 CA2612240 A1 CA 2612240A1
Authority
CA
Canada
Prior art keywords
seq
protein
nthi
ooe
hypothetical protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002612240A
Other languages
English (en)
French (fr)
Inventor
Lauren O. Bakaletz
Robert S. Munson, Jr.
David W. Dyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Oklahoma
Nationwide Childrens Hospital Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA2871088A priority Critical patent/CA2871088A1/en
Publication of CA2612240A1 publication Critical patent/CA2612240A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1242—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/285—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
CA002612240A 2005-06-16 2006-06-15 Genes of an otitis media isolate of nontypeable haemophilus influenzae Abandoned CA2612240A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2871088A CA2871088A1 (en) 2005-06-16 2006-06-15 Genes of an otitis media isolate of nontypeable haemophilus influenzae

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69121405P 2005-06-16 2005-06-16
US60/691,214 2005-06-16
PCT/US2006/023428 WO2006138527A2 (en) 2005-06-16 2006-06-15 Genes of an otitis media isolate of nontypeable haemophilus influenzae

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2871088A Division CA2871088A1 (en) 2005-06-16 2006-06-15 Genes of an otitis media isolate of nontypeable haemophilus influenzae

Publications (1)

Publication Number Publication Date
CA2612240A1 true CA2612240A1 (en) 2006-12-28

Family

ID=37057493

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002612240A Abandoned CA2612240A1 (en) 2005-06-16 2006-06-15 Genes of an otitis media isolate of nontypeable haemophilus influenzae
CA2871088A Abandoned CA2871088A1 (en) 2005-06-16 2006-06-15 Genes of an otitis media isolate of nontypeable haemophilus influenzae

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2871088A Abandoned CA2871088A1 (en) 2005-06-16 2006-06-15 Genes of an otitis media isolate of nontypeable haemophilus influenzae

Country Status (5)

Country Link
US (5) US8283114B2 (enExample)
EP (3) EP2343312A1 (enExample)
JP (5) JP2008546390A (enExample)
CA (2) CA2612240A1 (enExample)
WO (1) WO2006138527A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
BRPI0609460A2 (pt) * 2005-03-30 2010-04-13 Novartis Vaccines & Diagnostics Inc haemophilus influenzae tipo b
US8785130B2 (en) * 2005-07-07 2014-07-22 Bio-Id Diagnostic Inc. Use of markers including nucleotide sequence based codes to monitor methods of detection and identification of genetic material
US9132183B2 (en) * 2007-03-09 2015-09-15 Newport Laboratories Modified live (JMSO strain) Haemophilus parasuis vaccine
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
US8617574B2 (en) 2009-02-13 2013-12-31 Valneva Austria Gmbh Nontypable Haemophilus influenzae antigens
KR101334981B1 (ko) * 2010-06-10 2013-12-02 한국과학기술원 탄화수소 생성능을 가지는 변이 미생물 및 이를 이용한 탄화수소의 제조방법
WO2012099832A2 (en) * 2011-01-17 2012-07-26 Life Technologies Corporation Enzymatic ligation of nucleic acids
WO2012099896A2 (en) 2011-01-17 2012-07-26 Life Technologies Corporation Workflow for detection of ligands using nucleic acids
US20120276145A1 (en) * 2011-03-28 2012-11-01 House Research Institute Extracellular matrix proteins from haemophilus influenzae biofilms: targets for therapeutic or diagnostic use
CN103687613A (zh) * 2011-05-11 2014-03-26 里斯贝克保健瑞典股份公司 蛋白f-具有层粘连蛋白和玻连蛋白结合性能的新的流感嗜血杆菌粘附素
RU2727476C2 (ru) * 2012-04-26 2020-07-21 Новартис Аг Антигены и антигенные композиции
AU2014225330B2 (en) * 2013-03-08 2018-11-01 Lauren O. Bakaletz Transcutaneous dosage formulation
US9052314B2 (en) * 2013-03-14 2015-06-09 Silver Lake Research Corporation Biomarkers for detecting the presence of bacteria
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US9580758B2 (en) 2013-11-12 2017-02-28 Luc Montagnier System and method for the detection and treatment of infection by a microbial agent associated with HIV infection
US10624934B2 (en) 2014-03-06 2020-04-21 Research Institute At Nationwide Children's Hospital Prebiotic formulations
EP3113630B1 (en) * 2014-03-06 2019-12-11 The Research Institute at Nationwide Children's Hospital Probiotic formulations and methods for use
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3650043A3 (en) * 2015-06-09 2020-07-29 The Board of Regents of the University of Oklahoma Compositions and treatments for haemophilus influenzae
HK1255383A1 (zh) 2015-07-31 2019-08-16 The Research Institute At Nationwide Children's Hospital 去除生物膜的肽及抗體
CN106567949A (zh) * 2015-10-12 2017-04-19 海南广天恒科技发展有限公司 燃气阀专用限流装置
WO2017066719A2 (en) 2015-10-14 2017-04-20 Research Institute At Nationwide Children's Hospital Hu specific interfering agents
KR20180135493A (ko) * 2016-04-27 2018-12-20 바이오셀즈(베이징) 바이오테크 코., 엘티디. 흥분성 신경독성 관련 손상의 치료 방법
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2018129092A1 (en) 2017-01-04 2018-07-12 Research Institute At Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
EP3565589A1 (en) 2017-01-04 2019-11-13 Research Institute at Nationwide Children's Hospital Dnabii vaccines and antibodies with enhanced activity
EP3624684A4 (en) * 2017-05-18 2020-12-02 Neuraldx Ltd VESTIBULO-ACOUSTIC SIGNAL TREATMENT
CN107478627B (zh) * 2017-08-30 2019-09-10 温州大学激光与光电智能制造研究院 基于荧光纤维丝示踪的壁湍流时空演化过程检测方法
EP3860718A4 (en) 2018-10-05 2022-08-31 Research Institute at Nationwide Children's Hospital HMGB1 PROTEIN DERIVATIVES FOR BIOFILM REMOVAL
US20220143168A1 (en) * 2019-02-27 2022-05-12 Evaxion Biotech A/S Vaccines targeting H. influenzae
CN111693691B (zh) * 2019-03-14 2023-09-05 天津华科泰生物技术有限公司 一种基于卟啉结构的聚合物标签
US12453747B2 (en) 2019-06-03 2025-10-28 Research Institute At Nationwide Children's Hospital Prebiotic formulations for prevention of sepsis and necroenterocolitis induced neurodevelopmental deficiencies
CN112575041B (zh) * 2019-09-30 2022-12-13 江南大学 一种混合碳源高效发酵生产phb的工程菌及其应用
CN112808285B (zh) * 2021-01-14 2023-08-04 武汉科技大学 一种非均相类芬顿催化剂及其制备方法和应用
CN114574456B (zh) * 2022-03-18 2022-08-12 华南理工大学 一种亚硝酸盐还原酶突变体及其编码基因和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0821737A4 (en) * 1995-04-21 2005-01-19 Human Genome Sciences Inc NUCLEOTIDE SEQUENCE OF THE GENOME HAEMOPHILUS INFLUENZAE RD, THE FRAGMENTS THEREOF, AND ITS APPLICATIONS
DE19728833A1 (de) 1997-07-05 1999-01-07 Bayer Ag Verfahren zur Beseitigung von Oberflächengewässer verschmutzenden organischen Flüssigkeiten
ATE476508T1 (de) 1997-11-06 2010-08-15 Novartis Vaccines & Diagnostic Neisseriale antigene
JP2004537956A (ja) * 1999-01-22 2004-12-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規化合物
US6605709B1 (en) * 1999-04-09 2003-08-12 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Proteus mirabilis for diagnostics and therapeutics
GB0026002D0 (en) 2000-10-24 2000-12-13 Smithkline Beecham Biolog Novel compounds
JP2006519605A (ja) 2003-03-06 2006-08-31 チルドレンズ ホスピタル， インコーポレイテッド 類型不能ｈａｅｍｏｐｈｉｌｕｓｉｎｆｌｕｅｎｚａｅの中耳炎単離株の遺伝子
CA2520386A1 (en) * 2003-03-27 2004-10-14 Children's Hospital, Inc. Nontypeable haemophilus influenzae virulence factors
GB0410866D0 (en) * 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae

Also Published As

Publication number Publication date
US20140127221A1 (en) 2014-05-08
WO2006138527A2 (en) 2006-12-28
JP2016054739A (ja) 2016-04-21
JP2014147397A (ja) 2014-08-21
JP2017074071A (ja) 2017-04-20
JP2012120543A (ja) 2012-06-28
US20130078254A1 (en) 2013-03-28
US8652773B2 (en) 2014-02-18
WO2006138527A3 (en) 2007-03-29
CA2871088A1 (en) 2006-12-28
JP2008546390A (ja) 2008-12-25
US8283114B2 (en) 2012-10-09
US20160289278A1 (en) 2016-10-06
EP2343312A1 (en) 2011-07-13
EP2070945A1 (en) 2009-06-17
US20110135646A1 (en) 2011-06-09
US9034642B2 (en) 2015-05-19
US20150218231A1 (en) 2015-08-06
EP1899366A2 (en) 2008-03-19

Similar Documents

Publication Publication Date Title
US9034642B2 (en) Genes of an otitis media isolate of nontypeable Haemophilus influenzae
US7749518B2 (en) Polypeptides from non-typeable Haemophilus influenzae
US8628917B2 (en) Genes of an otitis media isolate of nontypeable Haemophilus influenzae
US7041814B1 (en) Nucleic acid and amino acid sequences relating to Enterobacter cloacae for diagnostics and therapeutics
US20120093868A1 (en) Haemophilus influenzae type b
US20040203093A1 (en) Nucleotide sequence of the haemophilus influenzae rd genome, fragments thereof, and uses thereof
JPH11501520A (ja) インフルエンザ菌Ｒｄゲノムのヌクレオチド配列、そのフラグメント及びその使用
US20050131222A1 (en) Nucleotide sequence of the haemophilus influenzae Rd genome, fragments thereof, and uses thereof
US20040219585A1 (en) Nontypeable haemophilus influenzae virulence factors
HK1133019A (en) Genes of an otitis media isolate of nontypeable haemophilus influenzae
EP1923399A1 (en) Genes of an otitis media isolate of nontypeable Haemophilus influenzae
HK1118839A (en) Genes of an otitis media isolate of nontypeable haemophilus influenzae

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20151117